• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

报告非小细胞肺癌患者中不同 ALK 检测平台分析的 EML4-ALK 新型断裂点和罕见的 PRKAR1A-ALK

A novel break site of EML4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients.

机构信息

Beijing Institute of Radiation Medicine, Beijing, China.

Department of Pathology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.

出版信息

Thorac Cancer. 2021 Oct;12(20):2773-2779. doi: 10.1111/1759-7714.14123. Epub 2021 Sep 6.

DOI:10.1111/1759-7714.14123
PMID:34490727
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8520815/
Abstract

BACKGROUND

detection of anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements in patients with non-small-cell lung cancer (NSCLC) has become a routine pathological diagnosis worldwide.

METHODS

there are three major conventional diagnostic methods for ALK fusions: fluorescent in situ hybridization (FISH); immunohistochemistry (Ventana IHC (D5F3)); and polymerase chain reaction (PCR). Next-generation sequencing (NGS) technology as is a new tool for ALK status detection with great potential. These four methods are highly consistent in detecting ALK status (coincidence rate >96%). However, discrepancies in ALK status have been found in some patients among these methods, which causes confusion for clinicians.

RESULTS AND CONCLUSION

in this study, we analyzed two patients whose ALK statuses were not consistent using these four methods. We explored the potential reasons for deviation of the test results and found a novel EML4-ALK break site, which had been not described previously.

摘要

背景

检测非小细胞肺癌（NSCLC）患者的间变性淋巴瘤受体酪氨酸激酶基因（ALK）重排已成为全球常规的病理诊断方法。

方法

ALK 融合的三种主要常规诊断方法为：荧光原位杂交（FISH）；免疫组织化学（Ventana IHC（D5F3））；和聚合酶链反应（PCR）。下一代测序（NGS）技术是一种用于检测 ALK 状态的新工具，具有很大的潜力。这四种方法在检测 ALK 状态方面高度一致（一致性>96%）。然而，在这些方法中，一些患者的 ALK 状态存在差异，这给临床医生带来了困惑。

结果与结论

在这项研究中，我们分析了使用这四种方法检测结果不一致的两名患者。我们探讨了测试结果偏差的潜在原因，并发现了一个以前未描述过的新型 EML4-ALK 断裂点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/cc30aac9e776/TCA-12-2773-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/0bf8c4831444/TCA-12-2773-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/ec8fcddd9760/TCA-12-2773-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/ad1f4adf3700/TCA-12-2773-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/c660613e890d/TCA-12-2773-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/cc30aac9e776/TCA-12-2773-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/0bf8c4831444/TCA-12-2773-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/ec8fcddd9760/TCA-12-2773-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/ad1f4adf3700/TCA-12-2773-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/c660613e890d/TCA-12-2773-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4ec1/8520815/cc30aac9e776/TCA-12-2773-g001.jpg

相似文献

1
A novel break site of EML4-ALK report and a rare PRKAR1A-ALK report analyzed by different ALK detection platforms in non-small cell lung cancer patients.报告非小细胞肺癌患者中不同 ALK 检测平台分析的 EML4-ALK 新型断裂点和罕见的 PRKAR1A-ALK
Thorac Cancer. 2021 Oct;12(20):2773-2779. doi: 10.1111/1759-7714.14123. Epub 2021 Sep 6.
2
Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.减弱的孤立 3' 信号：非小细胞肺癌中极具挑战性的 ALK FISH 治疗相关模式。
Lung Cancer. 2020 May;143:80-85. doi: 10.1016/j.lungcan.2020.03.007. Epub 2020 Mar 10.
3
Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.比较 FISH、IHC 和 NGS 检测 ALK 对预测晚期非小细胞肺癌患者接受克唑替尼治疗获益的影响。
Lung Cancer. 2019 May;131:62-68. doi: 10.1016/j.lungcan.2019.03.018. Epub 2019 Mar 20.
4
Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib.在中国非小细胞肺癌患者中同时进行 VENTANA IHC 和 RT-PCR 检测 ALK 状态及其对克唑替尼的反应。
J Transl Med. 2018 Apr 11;16(1):93. doi: 10.1186/s12967-018-1468-9.
5
Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.采用下一代测序方法检测肺癌患者中的已知和新型 ALK 融合转录本。
Sci Rep. 2017 Oct 2;7(1):12510. doi: 10.1038/s41598-017-12679-8.
6
Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.荧光原位杂交（FISH）和免疫组织化学组合分析揭示了 NSCLC 中 ALK 融合模式的罕见基因组事件，这些事件对克唑替尼治疗有反应。
J Thorac Oncol. 2017 Jan;12(1):94-101. doi: 10.1016/j.jtho.2016.08.145. Epub 2016 Sep 8.
7
Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.比较免疫组织化学（IHC）、荧光原位杂交（FISH）和 RT-PCR 方法在台湾 312 例非小细胞肺癌患者中检测 ALK 重排。
PLoS One. 2013 Aug 7;8(8):e70839. doi: 10.1371/journal.pone.0070839. eCollection 2013.
8
ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.采用靶向 RNA 下一代测序检测 ALK 融合变体和 ALK 阳性非小细胞肺癌对克唑替尼的临床反应。
Lung Cancer. 2018 Feb;116:15-24. doi: 10.1016/j.lungcan.2017.12.004. Epub 2017 Dec 8.
9
Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.对免疫组织化学（IHC）呈阳性且荧光原位杂交（FISH）呈阴性的ALK阳性肺腺癌患者使用克唑替尼的反应。
Oncotarget. 2016 Sep 27;7(39):64410-64420. doi: 10.18632/oncotarget.10560.
10
Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.使用 RT-PCR 检测 ALK 重排：与 NSCLC 患者的下一代测序相比，这是一种可靠的方法。
Mol Diagn Ther. 2021 Jul;25(4):487-494. doi: 10.1007/s40291-021-00532-8. Epub 2021 Jun 16.

引用本文的文献

1
The landscape of actionable genomic alterations in lung adenocarcinomas in India.印度肺腺癌中可操作的基因组改变情况
Front Genet. 2023 Dec 13;14:1256756. doi: 10.3389/fgene.2023.1256756. eCollection 2023.
2
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer.针对EML4-ALK驱动的肺癌，ALK抑制剂单药治疗的替代治疗方案
Cancers (Basel). 2022 Jul 15;14(14):3452. doi: 10.3390/cancers14143452.

本文引用的文献

1
Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.肺癌筛查，版本 3.2018，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2018 Apr;16(4):412-441. doi: 10.6004/jnccn.2018.0020.
2
Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.对免疫组织化学（IHC）呈阳性且荧光原位杂交（FISH）呈阴性的ALK阳性肺腺癌患者使用克唑替尼的反应。
Oncotarget. 2016 Sep 27;7(39):64410-64420. doi: 10.18632/oncotarget.10560.
3
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
综合基因组分析鉴定出一组荧光原位杂交未检测到的对克唑替尼敏感的ALK重排非小细胞肺癌。
Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.
4
Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer.中国非小细胞肺癌患者中EML4-ALK融合基因的检测及与表皮生长因子受体（EGFR）突变相关的特征
Onco Targets Ther. 2016 Apr 5;9:1989-95. doi: 10.2147/OTT.S100303. eCollection 2016.
5
Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas.非小细胞肺癌中 Ventana ALK（D5F3）伴随诊断检测的概况。
Expert Rev Mol Diagn. 2016 Jun;16(6):707-13. doi: 10.1586/14737159.2016.1172963. Epub 2016 Apr 15.
6
Genomic alterations in lung adenocarcinoma.肺腺癌中的基因组改变。
Lancet Oncol. 2015 Jul;16(7):e342-51. doi: 10.1016/S1470-2045(15)00077-7.
7
Refining the treatment of NSCLC according to histological and molecular subtypes.根据组织学和分子亚型细化 NSCLC 的治疗。
Nat Rev Clin Oncol. 2015 Sep;12(9):511-26. doi: 10.1038/nrclinonc.2015.90. Epub 2015 May 12.
8
Novel ALK fusion partners in lung cancer.肺癌中的新型 ALK 融合伙伴。
Cancer Lett. 2015 Jun 28;362(1):116-21. doi: 10.1016/j.canlet.2015.03.028. Epub 2015 Mar 23.
9
Global cancer statistics, 2012.全球癌症统计数据，2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
10
The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌分子检测的外部质量评估的相关性：两轮试点结果显示仍有优化空间。
PLoS One. 2014 Nov 11;9(11):e112159. doi: 10.1371/journal.pone.0112159. eCollection 2014.